CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 31 - 40 of 1145
Study Number Lead Group Study Title CIRB Study Status
AALL1821 COG A Phase 2 Study of Blinatumomab (NSC# 765986, IND #125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ≥ 1 to < 31 Years with First Relapse Pediatric CIRB Available to Open
E3805 ECOG CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer Adult CIRB - Late Phase Emphasis Available to Open
10508 ETCTN A Phase 1 Study of Nivolumab in Combination with ASTX727 in B-cell lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Adult CIRB - Early Phase Emphasis Available to Open
NSABP-B-40 NSABP A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens Adult CIRB - Late Phase Emphasis Available to Open
9681 ETCTN A Phase 1 Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and other Genitourinary Tumors. Adult CIRB - Early Phase Emphasis Available to Open
A151216 Alliance Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Adult CIRB - Late Phase Emphasis Available to Open
EA5161 ECOG-ACRIN Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC) Adult CIRB - Late Phase Emphasis Available to Open
S1900G SWOG A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) Adult CIRB - Late Phase Emphasis Available to Open
EA8134 ECOG-ACRIN InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) Adult CIRB - Late Phase Emphasis Available to Open
AAML1421 COG A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine; Cytarabine; and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML) Pediatric CIRB Available to Open
Displaying 31 - 40 of 1145